FY 2022 Financial Results & Business Update

March 27, 2023

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as "believes," "expects," "anticipates," "could," "would," "seeks," "aims," "plans," "potential," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen's business, Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the sufficiency of its cash resources, and the therapeutic potential of Acumen's product candidate, ACU193, including its potential for improved safety and efficacy as compared to other monoclonal antibodies in development, as well as the expectations concerning the INTERCEPT-AD trial and Acumen's planned Phase 2/3 clinical trial, including the expected timing of initiation, enrollment and reporting data, and risks and uncertainties relating to the progression and duration of the COVID-19 pandemic and responsive measures thereto and related effects on Acumen. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic. These and other risks concerning Acumen's programs are described in additional detail in Acumen's filings with the Securities and Exchange Commission ("SEC"), including in Acumen's most recent Annual Report Form 10-K and future filings and reports by Acumen. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. In this presentation, references to cash also include cash equivalents.

ACUMEN

Agenda

- **FY 2022 Business Update**

  Dan O'Connell, Chief Executive Officer

- **ACU193 Clinical Trial Update**

  Dr. Eric Siemers, Chief Medical Officer

- **FY 2022 Financial Results**

  Matt Zuga, Chief Business Officer & Chief Financial Officer

INTERCEPT-AD Trial Update

- **INTERCEPT-AD: Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease (AD) (RCT)**
  - → Enrollment completed in February 2023
  - → Topline results, safety and clinical proof-of-mechanism following full database lock expected in Q3 2023
  - → Cohort 7 dose level amended to 25 mg/kg every two weeks (Q2W) from 60 mg/kg Q2W prior to start
    - Preliminary, blinded plasma pharmacokinetic (PK) data demonstrated higher-than-expected ACU193 exposures at all dose levels
    - Preliminary Cohort 3 (SAD 25 mg/kg) dose results in Day 21 cerebrospinal fluid (CSF) ACU193 levels in excess of reported soluble amyloid beta oligomer (AβO) levels
    - Two blinded observations of asymptomatic ARIA-E factored into decision to amend Cohort 7 dose; one in Cohort 4 (after single 60 mg/kg dose) and one in Cohort 5 (after third 10 mg/kg dose)
    - Cohort 6 is fully enrolled with planned dose (60 mg/kg every four weeks (Q4W))
  - → Actively preparing for Phase 2/3 activities in anticipation of successful results from our Phase 1 study
    - Will propose an end-of-Phase 2 meeting with the FDA to be held in Q4 2023 to discuss the design of our Phase 2/3 study that incorporates an interim decision to expand the size from a Phase 2 to a Phase 3 study

INTERCEPT-AD Phase 1 Topline Results Expected in Q3 2023

- **Phase 1 is a randomized placebo controlled first-in-human, SAD/MAD study with 65 patients enrolled with early Alzheimer's Disease.**
  - → Objectives of the trial are to evaluate safety and tolerability, evaluate PK, and establish target engagement for ACU193 administered intravenously
  - → The primary trial endpoints are focused on safety and PK
- **Safety**
  - → Preliminary blinded cases of ARIA-E observed in Q1 were aligned with safety expectations for ACU193
  - → ARIA-E cases provide evidence of central pharmacology
- **PK**
  - → Preliminary CSF PK data from our 25 mg/kg cohort showed ACU193 levels are substantially above reported levels of oligomers
- **Target engagement**
  - → Assay is designed to measure the complex of Aβ oligomers bound to ACU193 in CSF
  - → Will perform test runs of this assay prior to our database lock

Acumen is Well Capitalized, With Expected Cash Runway Through 2025

MILESTONES	STATUS/ EXPECTED TIMING
Initiated Ph1 clinical trial INTERCEPT-AD	✓
INTERCEPT-AD enrollment complete	✓
Proof-of-mechanism topline results	Q3 2023

~$193M

Cash, cash equivalents and marketable securities as of December 31, 2022

We believe that Acumen has the organizational expertise and cash and marketable securities on hand to advance ACU193 through 2025.

ACUMEN